search
Back to results

The Effect of Amiloride and Spironolactone in Healthy Persons (SPAS)

Primary Purpose

High Blood Pressure

Status
Completed
Phase
Phase 1
Locations
Denmark
Study Type
Interventional
Intervention
Amiloride
Spironolactone
Placebo
Placebo and spironolactone
Spironolactone
Sponsored by
Regional Hospital Holstebro
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for High Blood Pressure

Eligibility Criteria

18 Years - 40 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy
  • Non-smokers

Exclusion Criteria:

  • Smoking
  • Under medical treatment

Sites / Locations

  • Medical Research

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Placebo Comparator

Arm Label

Randomisation 1

Randomisation 2

Placebo

Arm Description

Amiloride 5 mg twice daily for 28 days, later compared with spironolactone and placebo

Spironolactone 25 mg twice daily, to be compared with placebo and amiloride

calcium tablet

Outcomes

Primary Outcome Measures

Blood pressure

Secondary Outcome Measures

Full Information

First Posted
March 6, 2009
Last Updated
July 7, 2011
Sponsor
Regional Hospital Holstebro
search

1. Study Identification

Unique Protocol Identification Number
NCT00857909
Brief Title
The Effect of Amiloride and Spironolactone in Healthy Persons
Acronym
SPAS
Official Title
The Effect of Amiloride and Spironolactone Measured on Cardiovascular and Kidney Related Variables in Healthy Subjects in a Double-blinded, Randomised, Placebo-controlled, Cross-over Study
Study Type
Interventional

2. Study Status

Record Verification Date
July 2011
Overall Recruitment Status
Completed
Study Start Date
January 2009 (undefined)
Primary Completion Date
July 2010 (Actual)
Study Completion Date
July 2010 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Regional Hospital Holstebro

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study will investigate whether retaining potassium in the body will lead to changes in blood pressure and changes in blood and urine samples.
Detailed Description
The purpose is to measure the effect of amiloride and spironolactone on: Renal function (GFR, u-AQP2, u-ENaCβ, u-cAMP, u-PGE2, CH20, FENa, FEK), Pulsbewave velocity, augmentation index and central blood pressure, Vasoactive hormones (PRC, AngII, Aldo, AVP, ANP, BNP and Endot), and Ambulatory blood pressure

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
High Blood Pressure

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Randomisation 1
Arm Type
Active Comparator
Arm Description
Amiloride 5 mg twice daily for 28 days, later compared with spironolactone and placebo
Arm Title
Randomisation 2
Arm Type
Active Comparator
Arm Description
Spironolactone 25 mg twice daily, to be compared with placebo and amiloride
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
calcium tablet
Intervention Type
Drug
Intervention Name(s)
Amiloride
Intervention Description
1 tablet twice a day
Intervention Type
Drug
Intervention Name(s)
Spironolactone
Intervention Description
1 tablet twice a day
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo
Intervention Type
Drug
Intervention Name(s)
Placebo and spironolactone
Intervention Description
5mg twice daily
Intervention Type
Drug
Intervention Name(s)
Spironolactone
Intervention Description
25mg twice daily
Primary Outcome Measure Information:
Title
Blood pressure
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy Non-smokers Exclusion Criteria: Smoking Under medical treatment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Erling B Pedersen, Prof
Organizational Affiliation
Regional Hospital Holstebro
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medical Research
City
Holstebro
ZIP/Postal Code
7500
Country
Denmark

12. IPD Sharing Statement

Learn more about this trial

The Effect of Amiloride and Spironolactone in Healthy Persons

We'll reach out to this number within 24 hrs